Ventas (NYSE:VTR) Upgraded by Zacks Investment Research to “Hold”


Share on StockTwits

Ventas (NYSE:VTR) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report released on Thursday, Zacks.com reports. The firm presently has a $58.00 price objective on the real estate investment trust’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 6.42% from the company’s previous close.

According to Zacks, “Ventas’ office segment is likely to benefit from the rising need for healthcare service delivery. Increasing longevity of the aging U.S. population and biopharma drug opportunities have promoted the life science and medical-market fundamentals. This is likely to boost the demand for the company’s office assets. Also, with diversified portfolio of healthcare properties, Ventas is well-poised to capitalize on the expenditure trend of senior citizens on healthcare services. The company is making efforts to bolster its balance-sheet strength and enhance financial flexibility. However, its shares have underperformed its industry in the past month. Also, Ventas’ senior housing business continues to bear the brunt of the COVID-19 outbreak. These woes are expected to continue, hindering occupancy and net operating income (NOI) growth.”

Other research analysts have also issued research reports about the stock. Robert W. Baird began coverage on shares of Ventas in a research report on Tuesday, January 5th. They issued a “neutral” rating and a $49.00 price target for the company. Mizuho increased their price target on shares of Ventas from $38.00 to $45.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 9th. Smith Barney Citigroup increased their price target on shares of Ventas from $35.00 to $50.00 in a research report on Tuesday, December 15th. Wells Fargo & Company increased their price target on shares of Ventas from $40.00 to $50.00 in a research report on Thursday, March 11th. Finally, Morgan Stanley increased their price target on shares of Ventas from $52.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Monday, March 22nd. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $47.16.

Shares of VTR opened at $54.50 on Thursday. The company has a 50-day simple moving average of $54.34 and a 200-day simple moving average of $48.43. The firm has a market capitalization of $20.42 billion, a P/E ratio of 49.55, a P/E/G ratio of 4.34 and a beta of 1.06. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.53 and a current ratio of 1.53. Ventas has a 52 week low of $25.38 and a 52 week high of $58.10.

Ventas (NYSE:VTR) last announced its quarterly earnings data on Thursday, February 18th. The real estate investment trust reported $0.29 EPS for the quarter, missing the Zacks’ consensus estimate of $0.73 by ($0.44). Ventas had a net margin of 10.49% and a return on equity of 3.88%. During the same quarter last year, the business posted $0.03 EPS. As a group, equities analysts forecast that Ventas will post 3.17 earnings per share for the current year.

In related news, Director Richard I. Gilchrist sold 8,934 shares of the firm’s stock in a transaction on Wednesday, March 24th. The shares were sold at an average price of $54.04, for a total value of $482,793.36. Following the completion of the transaction, the director now owns 41,210 shares of the company’s stock, valued at $2,226,988.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Robert F. Probst sold 5,100 shares of the firm’s stock in a transaction on Thursday, March 11th. The shares were sold at an average price of $58.00, for a total transaction of $295,800.00. Following the completion of the transaction, the chief financial officer now directly owns 141,506 shares of the company’s stock, valued at approximately $8,207,348. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,086 shares of company stock valued at $3,073,810. 1.16% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Ventas in the 4th quarter valued at about $25,000. Inspire Advisors LLC bought a new stake in shares of Ventas during the 4th quarter worth about $25,000. Orion Capital Management LLC bought a new stake in shares of Ventas during the 4th quarter worth about $25,000. Arlington Partners LLC bought a new stake in shares of Ventas during the 4th quarter worth about $26,000. Finally, Johnson Midwest Financial LLC bought a new stake in shares of Ventas during the 4th quarter worth about $26,000. 90.54% of the stock is owned by institutional investors.

About Ventas

Ventas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries Â- healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population.

Featured Article: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on Ventas (VTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ventas (NYSE:VTR)

Receive News & Ratings for Ventas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventas and related companies with MarketBeat.com's FREE daily email newsletter.